Average Price Target: $33.43
▲ +147.44% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for ChemoCentryx in the last 3 months. The average price target is $33.43, with a high forecast of $70.00 and a low forecast of $17.00. The average price target represents a 147.44% upside from the last price of $13.51.
The current consensus among 8 investment analysts is to hold stock in ChemoCentryx. This rating has held steady since February 2021, when it changed from a Buy consensus rating.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.